MediciNova
MediciNova, Inc. is a biopharmaceutical company based in La Jolla, California, established in 2000. The company specializes in acquiring and developing novel small-molecule therapeutics aimed at treating serious diseases with unmet medical needs, primarily within the United States. MediciNova's product pipeline includes MN-166, an oral anti-inflammatory and neuroprotective agent for neurological disorders such as multiple sclerosis and amyotrophic lateral sclerosis; MN-221, a selective beta-2-adrenergic receptor agonist for acute asthma exacerbations; and MN-001, a small molecule for fibrotic diseases like nonalcoholic steatohepatitis. Additionally, MediciNova is involved in the development of MN-029, a tubulin binding agent for solid tumors, and collaborates with BioComo and Mie University on a SARS-CoV-2 vaccine. The company’s strategic alliances, particularly with Japanese pharmaceutical firms, enhance its diversified portfolio of clinical and preclinical candidates, which are characterized by their differentiated therapeutic profiles and significant commercial potential.
Top Regions
Top Stages
1 past transactions
Avigen
Acquisition in 2009
Avigen, Inc., a biopharmaceutical company, engages in identifying and developing products to treat patients with neurological and other disorders. The company develops the AV411 portfolio, which includes the phase II-stage lead drug compound and proprietary analogs and represents novel, non-opioid drugs for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6; and a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. AV411 is being evaluated in Phase Ib/IIa clinical trials. The company was founded in 1992 and is headquartered in Alameda, California. As of December 18, 2009, Avigen, Inc. operates as a subsidiary of MediciNova Inc
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.